A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
The user reports regrowth after 5 months using Minoxidil, finasteride, microneedling with a derma stamp, Nizoral shampoo, multivitamins, and biotin, and has shared progress pictures. They apply treatments daily, microneedle twice a week, and exercise regularly, noting an improvement in their mental well-being.
A 19-year-old user shared impressive hair growth results after using 5% topical minoxidil foam and 1mg finasteride for two months, along with vitamin D. They recommend this regimen for others, noting significant improvements in hair thickness and health.
A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.
The user experienced improved hair at 6 months using 0.5 mg finasteride daily but noticed more scalp visibility and potential hair loss at 13 months, questioning if this was due to shedding or the treatment not working. Some respondents suggested the possibility of a shed or scalp inflammation, while others observed improvements or advised checking for underlying scalp conditions.
The conversation discusses hair loss treatments, with users suggesting the use of finasteride daily, considering minoxidil for aggressive hair loss, and discussing the normalcy of shedding during treatment. Some users recommend adding Nizoral shampoo and switching to dutasteride for better results.
The user has been on a hair loss treatment for 14 months using dutasteride and oral minoxidil without seeing regrowth and is considering adding more drugs due to the psychological impact of hair loss. However, replies suggest the user may not actually be experiencing noticeable hair loss.
A user shared a 3-month hair regrowth transformation using Finasteride 1mg, Minoxidil, and occasional derma rolling. Some responders are skeptical of the rapid growth, while others suggest the user might be an exceptional responder to the treatment.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.
The user has been using a strong combination of hair loss treatments for 16 months, including Finasteride, Minoxidil, Dutasteride, and RU-58841, but their hair loss has worsened. They're questioning whether their high testosterone levels or residual scalp DHT are causing further hair loss, with a reply suggesting that even small amounts of DHT can cause hair loss if one is sensitive to it.
The user has been using a topical solution of Minoxidil and Finasteride for hair regrowth for 11 months, applying it three times a week. The responses to the user's question about regrowth are mixed, with some users confirming regrowth and others suggesting it's time to give up.
The conversation is about the effectiveness of finasteride (fin) in preventing hair loss after a hair transplant. Some users have experienced hair thinning and loss after stopping finasteride, while others have had success with finasteride and minoxidil (min) in maintaining their transplanted hair. The general consensus is that finasteride is important for younger patients to prevent further hair loss.
A user's one-year progress in hair loss treatment using finasteride and minoxidil. The user shared their experience and advice, including adjusting the amount of sprays used based on individual needs and the importance of patience and positivity in the process.
Hair loss discussion mentions losing 50 strands daily as normal, but varies for individuals. Some users joke about hair loss in other areas, while others emphasize individual differences and hair cycle length.
User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.
User shared 2-year progress with Dutasteride, 5mg oral minoxidil, and 7 months of RU58841 for hair growth. RU58841 was most effective, stopping itching and promoting significant growth.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
A user who is trying alternative treatments, such as mucuna pruriens dissolved in water/alcohol and a blend of jojoba oil, rosemary oil, and peppermint oil, for hair loss. Other users have shared anecdotal evidence, discussed the potential effectiveness of certain treatments, and questioned the time sensitivity of experimenting with new treatments.
A user with early-stage diffuse hair thinning asked for long-term success stories using treatments like finasteride, minoxidil, and RU58841. One person regained most of their hair after 22 months on finasteride and minoxidil, while another saw significant improvement with oral minoxidil after trying various treatments over many years.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.